Free Trial

Lyra Therapeutics (LYRA) Competitors

Lyra Therapeutics logo
$9.06 -0.24 (-2.58%)
Closing price 04:00 PM Eastern
Extended Trading
$9.10 +0.04 (+0.50%)
As of 06:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LYRA vs. DXR, ECOR, NEPH, MODD, QTI, SPAI, POCI, NMTC, PYPD, and TMDIF

Should you be buying Lyra Therapeutics stock or one of its competitors? The main competitors of Lyra Therapeutics include Daxor (DXR), electroCore (ECOR), Nephros (NEPH), Modular Medical (MODD), QT Imaging (QTI), Safe Pro Group (SPAI), Precision Optics (POCI), NeuroOne Medical Technologies (NMTC), PolyPid (PYPD), and Titan Medical (TMDIF). These companies are all part of the "medical equipment" industry.

Lyra Therapeutics vs. Its Competitors

Daxor (NASDAQ:DXR) and Lyra Therapeutics (NASDAQ:LYRA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.

Daxor has a net margin of 0.00% compared to Lyra Therapeutics' net margin of -6,711.39%. Daxor's return on equity of 0.00% beat Lyra Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
DaxorN/A N/A N/A
Lyra Therapeutics -6,711.39%-295.52%-66.95%

In the previous week, Lyra Therapeutics had 1 more articles in the media than Daxor. MarketBeat recorded 2 mentions for Lyra Therapeutics and 1 mentions for Daxor. Daxor's average media sentiment score of 0.00 equaled Lyra Therapeutics'average media sentiment score.

Company Overall Sentiment
Daxor Neutral
Lyra Therapeutics Neutral

1.3% of Daxor shares are owned by institutional investors. Comparatively, 95.6% of Lyra Therapeutics shares are owned by institutional investors. 59.5% of Daxor shares are owned by company insiders. Comparatively, 3.3% of Lyra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Daxor has higher revenue and earnings than Lyra Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Daxor$2.13M21.56N/AN/AN/A
Lyra Therapeutics$1.19M10.13-$93.43M-$60.50-0.15

Daxor currently has a consensus target price of $25.00, suggesting a potential upside of 163.16%. Lyra Therapeutics has a consensus target price of $100.00, suggesting a potential upside of 1,003.75%. Given Lyra Therapeutics' higher possible upside, analysts clearly believe Lyra Therapeutics is more favorable than Daxor.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Daxor
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Lyra Therapeutics
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33

Daxor has a beta of -0.07, suggesting that its share price is 107% less volatile than the S&P 500. Comparatively, Lyra Therapeutics has a beta of 0.24, suggesting that its share price is 76% less volatile than the S&P 500.

Summary

Daxor beats Lyra Therapeutics on 7 of the 11 factors compared between the two stocks.

Get Lyra Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for LYRA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LYRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LYRA vs. The Competition

MetricLyra TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$12.00M$2.42B$5.57B$9.02B
Dividend YieldN/A1.80%5.25%4.03%
P/E Ratio-0.159.3827.1820.14
Price / Sales10.13628.97417.49184.08
Price / CashN/A161.3437.0657.97
Price / Book1.024.698.085.60
Net Income-$93.43M$31.26M$3.16B$248.50M
7 Day Performance0.50%6.81%3.77%5.15%
1 Month Performance-41.55%4.12%3.90%7.62%
1 Year Performance-38.09%4.05%34.22%21.56%

Lyra Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LYRA
Lyra Therapeutics
1.6565 of 5 stars
$9.06
-2.6%
$100.00
+1,003.8%
-31.4%$12.00M$1.19M-0.1550
DXR
Daxor
N/A$9.86
+0.3%
$25.00
+153.5%
+8.1%$47.72MN/A0.0037Gap Down
ECOR
electroCore
2.3581 of 5 stars
$6.09
-0.3%
$25.50
+318.7%
+25.5%$45.19M$25.18M-3.9050
NEPH
Nephros
1.6244 of 5 stars
$4.08
+1.2%
$5.00
+22.5%
+82.8%$43.25M$15.52M58.2930Positive News
High Trading Volume
MODD
Modular Medical
N/A$0.73
-0.2%
N/A-51.9%$39.53MN/A-1.4320Gap Up
QTI
QT Imaging
N/A$1.42
-1.5%
N/A+181.1%$38.48M$4.00M0.00N/A
SPAI
Safe Pro Group
N/A$2.50
-5.3%
N/AN/A$37.93M$2.17M-3.0911News Coverage
Gap Down
POCI
Precision Optics
N/A$4.89
+1.2%
N/A-19.9%$37.51M$19.10M-5.4980
NMTC
NeuroOne Medical Technologies
2.2548 of 5 stars
$0.73
+4.3%
$1.45
+98.4%
-21.1%$36.42M$3.45M-3.3220
PYPD
PolyPid
1.9515 of 5 stars
$3.45
-1.4%
$11.80
+242.0%
-12.5%$35.16MN/A-0.8080Gap Down
TMDIF
Titan Medical
N/A$0.28
-1.7%
N/A+709.9%$31.93M$17.63M-0.2250Gap Up

Related Companies and Tools


This page (NASDAQ:LYRA) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners